Pancreatic Cancer Trial, Recruiting (NCT06389552)

Pancreatic Cancer Trial, Recruiting NCT06389552 Sponsor: HK inno.N Corporation Condition: Pancreatic Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06389552 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Pancreatic Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are 20 years of age or older at the time of signing the consent form
People who are planned to receive a chemotherapy treatment called FOLFIRINOX after surgery for pancreatic cancer
People who have a good general health and activity level, rated as 0 or 1 on a standard medical scale (confirm with trial site)
People who are scheduled to have a type of surgery that aims to fully or nearly fully remove the cancer (confirm with trial site)
People whose organs (such as liver and kidneys) are functioning well enough to safely receive chemotherapy

Who may not be able to join:

People for whom the chemotherapy treatment FOLFIRINOX is considered unsafe or not recommended based on official drug approval guidelines
People who are receiving treatment aimed at managing symptoms rather than attempting to cure the cancer
People who have previously had a severe reaction or allergic response to the FOLFIRINOX chemotherapy treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 21 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Myung-Ah Lee, Seoul St. Mary's Hospital

Phone: 82-2-6477-0252

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06389552

Sponsor: HK inno.N Corporation

Phase: Not Applicable

Status: Recruiting

Condition: Pancreatic Cancer

Trial contact: 82-2-6477-0252

More information: https://clinicaltrials.gov/study/NCT06389552

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are 20 years of age or older at the time of signing the consent form
People who are planned to receive a chemotherapy treatment called FOLFIRINOX after surgery for pancreatic cancer
People who have a good general health and activity level, rated as 0 or 1 on a standard medical scale (confirm with trial site)
People who are scheduled to have a type of surgery that aims to fully or nearly fully remove the cancer (confirm with trial site)
People whose organs (such as liver and kidneys) are functioning well enough to safely receive chemotherapy

Who may not be able to join:

People for whom the chemotherapy treatment FOLFIRINOX is considered unsafe or not recommended based on official drug approval guidelines
People who are receiving treatment aimed at managing symptoms rather than attempting to cure the cancer
People who have previously had a severe reaction or allergic response to the FOLFIRINOX chemotherapy treatment

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

HK inno.N Corporation

Registry

ClinicalTrials.gov

Start date

25 September 2023

Est. completion

1 December 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Disease-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov